Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
|Articles|June 8, 2020

Managing the COVID-19 Drug Safety Response

Author(s)MyMeds&Me

Current safety reporting systems cannot meet the demands of a COVID-19 response. Find out how digital transformation enables rapid understanding & management of drug safety.

Whitepapers

Related Content

Navigating Sunshine Act & State Transparency Laws

May 6th 2026

The RWE Backlog Problem

ByHealthVerity
May 4th 2026

Accelerating early RWE exploration without increasing analytic burden

ByHealthVerity
May 4th 2026

Validating HealthVerity eXOs: An agentic AI platform for real-world evidence

ByHealthVerity
May 4th 2026

The Ways Pharma Leaders are Rewiring their Organizations for Launch Success

ByInizio
March 31st 2026

Trending on PharmExec

1

Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables

2

Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu

3

Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu

4

The Questions You Couldn’t Ask in Time: How Agentic AI Accelerates Market Entry

5

FDA Approves Beqalzi for Relapsed or Refractory Mantle Cell Lymphoma, Inqovi in Combination with Venetoclax

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us